Denny Won

Cooley advised the underwriters of Heartflow, a leader in artificial intelligence technology for coronary artery disease, in connection with Heartflow’s $364.2 million upsized initial public offering.

Cooley advised the underwriters of Shoulder Innovations, a medical technology company exclusively focused on transforming the shoulder surgical care market, in connection with Shoulder Innovations’ $75 million initial public offering (IPO).

Cooley advised the underwriters of Aardvark Therapeutics, a phase 3 biotech company developing novel small-molecule therapies for metabolic diseases, in connection with Aardvark’s $94.2 million initial public offering (IPO).

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.

Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.